Core Viewpoint - The company, Zhongyou Technology, has issued a notice indicating that its recent daily operations are normal and there have been no significant changes in its business activities [1] Group 1: Company Operations - The company has conducted a self-inspection and confirmed that its daily operations are functioning normally [1] - There have been no major changes in the market environment or industry policies affecting the company [1] - Product research, production, and sales are progressing normally, and internal operational order is stable [1] Group 2: Shareholder and Market Impact - The company's controlling shareholder and actual controller do not have any significant matters that could affect abnormal fluctuations in the company's stock trading [1] - There are no other undisclosed significant information or events that could have a substantial impact on the company's stock price [1] - The company acknowledges recent short-term stock price volatility and advises investors to be cautious in the secondary market [1]

Core Viewpoint - Yong'an Pharmaceutical's stock price has experienced significant volatility, including a rapid rise followed by a sharp decline, influenced by market rumors and internal management changes [1][4]. Company Overview - Yong'an Pharmaceutical (002356.SZ) has a total market capitalization of 3.551 billion yuan as of May 7, with a recent stock price increase of 3.7% [2]. - The company primarily engages in the research, production, and sales of three categories of products: taurine, health foods, and special dietary foods (creatine) [6]. Recent Developments - The stock price surged due to rumors of a fivefold increase in taurine prices, which were later confirmed to be false by the company [4]. - On May 5, the company's chairman, Chen Yong, was placed under investigation, leading to a temporary leadership change with his son, Chen Zidi, stepping in as acting chairman [6][7]. Financial Performance - For the year 2024, Yong'an Pharmaceutical reported revenues of 839 million yuan, a year-on-year decrease of 13.78%, with taurine sales contributing 635 million yuan, accounting for 75.67% of total revenue [7]. - The net profit attributable to shareholders for 2024 was 61.766 million yuan, marking a significant increase of 601.65% compared to the previous year, indicating a turnaround from losses [7]. - In the first quarter of 2025, the company reported revenues of 171 million yuan, a decline of 12.96%, and a net loss of 4.3672 million yuan, a decrease of 115.23% year-on-year [7].